MRF-Logo2019-Horizontal-RGB
Prospective study of Ct-DNA blood testing and Tumor Mutational burden in Germany
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Prospective study of Ct-DNA blood testing and Tumor Mutational burden in Germany

› Forums › Cutaneous Melanoma Community › Prospective study of Ct-DNA blood testing and Tumor Mutational burden in Germany

  • This topic is empty.
  • Post
    • July 17, 2019 at 5:08 pm
    ed williams
    Participant
      Small prostective trial of 35 melanoma patients with various types of melanoma including uveal, acral, mucosal, occult and cutaneous getting ipi+nivo were studied for biomarkers that might predict response to check point inhibitors. This is a small trial done in Germany but shows what the future might look like for melanoma patients. https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0659-0

    Tagged: , , ,

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics